Current NCS Clinical Trials

Bone Marrow Failure
Examination of PHN in BM Failure Syndromes 06141- One Blood Sample (414/500)

Breast
Adjuvant HER2-Neg 06090-Ph3 TC vs. TAC x 6 cycles (389/2000)
Adjuvant 05053-Pilot Tamoxifen -->Femara Women ages 40-49 (116/300)
Met 1st 07036 Ph3 SU011248+Taxol vs Avastin+Taxol (35/75)
Met 1st or 2nd 04111-Ph2 Doxil/Carbo (HER2-Neg/Taxane-Neg only) (130/135)
Met 1st/2nd 07030-Ph1/2 Wkly Taxol+AEG35156 (Antisense Inhibitor of XIAP) (6/12) TOPS
Met 1st-3rd Triple Neg 07040-Ph2 Gemzar/Carbo +/- BSI-201 (39/75)
Met. 2-4th HER2-Pos 07067-Ph2 Trastuzumab-MCC-DM1 (35/55)
Met 3-6th (prior Anthracycline/Taxane req.) 06057-Ph3 E7389 vs Phy Choice (71/75)

Colon-Rectal
Locally Adv Rectal 05102-Ph2 Pre-Op RT + CIV 5FU +/- Cetuximab (42/130)
Met 1st 06010-Ph2 FOLFOX/AG-013736 v FOLFOX/Bev v FOLFOX/AG-013736+Bev (20/50)
Met 2nd 07141-Ph 2 FOLFIRI+Panitumumab vs FOLFIRI+Avastin (3/45)

Gastric/Esophageal
Met 1st Line 06063-Ph2 Docetaxel/Oxaliplatin +/- Cetuximab (23/150)

GYN - Fallopian(FT), Peritoneal(P), Ovarian(Ov), Uterine(U)
FT/P/OV-Platinum Sensitive, 1st Recurrence 07056-Ph2 Gem/Carbo +/- Avastin (13/60)
FT/P/Ov- Taxane/Platinum Refract/Resist 05076-Ph 3 Patupilone vs Doxil (32/75)
Ov/U-ErbB2+ Salvage after failing all poss.approved tx 06155-Ph2 Lapatinib (64/250)

ITP
Severly Refractory ITP NONUSON i1232- AMG 531 injections (4/?)

Kidney
2nd 07134 Ph2 Perifosine for Met Ca of the Kidney that has Progressed on a VEGF Receptor Inh 10/40

Leukemia
CLL Stage 2 or higher, 2nd Line 06180- Ph1B GCS-100 (6/12) TOPS
CML-CP Newly Diagnosed Ph+ 06189-Ph3 Imatinib vs Nilotinib (12/30)

Lung- NSCLC
Adjuv Stg IB-IIIA 06026-Ph3 Tarceva/Plac Post Resection+/-Chemo, EGFR + (42/180)
Relapsed after NeoAdj or Adj Chemo 05121-Ph2 Alim/Carbo v Alimta vs Alim/Gem(13/50)
Adv 1st 07031-Ph1/2 Taxol/Carbo + AEG35156(Antisense Inhibitor of XIAP)(8/12) TOPS CALL
2nd 04107-Ph3 Taxotere +/- Erbitux vs Alimta +/- Erbitux (341/400)
2nd 07027-Ph1b IMO-2055 + Erlotinib + Bevicizumab (6/24) TOPS CALL

Lung- SCLC
2nd Line s/p platinum tx 07050-Ph3 Amrubicin vs. Topotecan (21/56)
Relapsed 2nd-4th Line 05012-Ph I Wkly BB-10901 f/b Ph II EE (7/15) TOPS

Lymphoma
CR or CRu patients 05007-Ph3 Enzastaurin/Placebo (21/45)
Refractory/Relapsed Follicular 06138- Ph3 Rituxan/Galiximab vs. Rituxan/Placebo (7/60)
Relapsed/Refractory Peripheral T-Cell 06102-Ph2 Romidepsin (3/19)
Adv 05033- Ph1 CGC-11047 w/ Gem, Docetaxel, Avastin or Erlotinib (70/60) TOPS HOLD

Pancreatic
Post-Resection 05089-Ph2 GI-4000+Gemzar vs. Placebo+Gemzar (16/32)
1st/2nd line Stg2-4 Unresectable 06150-Ph1/2 Gem+/- RTA402 (18/12)TOPS
Met 1st line 07111-Ph 2 Gemzar+Amplimexon vs Gemzar+Placebo (2/30)

Prostate
Met 1st line 07068-Ph2 AT-101/q3wk Docetaxel/Pred vs q3wk Docetaxel/Pred (31/60)
Met 2nd after Taxotere 06118-Ph 2 Mitoxantrone/Pred +/- Cetuximab (0/115)

Rectal
Locally Adv Rectal 05102-Ph2 Pre-Op RT + CIV 5FU +/- Cetuximab (44/130)

Solid Tumor
Adv Tumors w/ Neuroendocrine Features 05125-Ph1 (SVV-001) (14/15) TOPS
Adv 05033- Ph1 CGC-11047 w/ Gem, Docetaxel, Avastin or Erlotinib (70/60) TOPS HOLD

Current trials as of Mar. 11, 2008